SLC5A2 and diabetic kidney disease: Moreover, among emerging or existing therapies being tested to control DKD progression, the SGLT2 inhibitor empagliflozin restored GEC fenestration density in leptin-deficient mice despite no expression of SGLT2 in GECs in these mice [19].